Gliknik Raises $11.5M in Series C Financing Gliknik Inc., a Baltimore, MD-based immunology company dedicated to patients with cancer and autoimmune disorders, completed an $11.5m Series C financing. The round was led by First In Ventures (FIV) with participation from SAISO Partners and affiliates of RDA Ventures and Garden Street Holdings. Kyle Rusconi, a founder of FIV, is joining the Gliknik Board. Led by CEO David Block, Gliknik is an immunology company creating and advancing biologic drugs for patients with cancer and autoimmune disorders. The company, which has secured $81m to date, intends to use the funds to progress the pipeline of its product candidates, including: